Mitsubishi Ufj Trust & Banking Corp Sarepta Therapeutics, Inc. Transaction History

Mitsubishi Ufj Trust & Banking Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$69.38 - $86.75 $3.04 Million - $3.8 Million	-43,769 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$72.25 - $168.95 $810,861 - $1.9 Million	-11,223 Reduced 20.41%	43,769 $3.31 Million
Q4 2020 Feb 12, 2021	SELL	$125.56 - $178.74 $237,182 - $337,639	-1,889 Reduced 3.32%	54,992 $9.38 Million
Q3 2020 Nov 12, 2020	SELL	$127.12 - $172.34 $192,713 - $261,267	-1,516 Reduced 2.6%	56,881 $7.99 Million
Q2 2020 Sep 11, 2020	SELL	$93.0 - $171.7 $185,349 - $342,198	-1,993 Reduced 3.3%	58,397 $9.36 Million
Q2 2020 Aug 13, 2020	BUY	$93.0 - $171.7 $218,364 - $403,151	2,348 Added 4.05%	60,390 $9.36 Million
Q1 2020 May 13, 2020	BUY	$82.38 - $131.64 $297,474 - $475,352	3,611 Added 6.63%	58,042 $5.68 Million
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $105,764 - $187,371	-1,382 Reduced 2.48%	54,431 $7.02 Million
Q3 2019 Nov 12, 2019	BUY	$72.81 - $156.91 $4.06 Million - $8.76 Million	55,813 New	55,813 $4.2 Million

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Trust & Banking Corp, based on Form 13F filings with the SEC.

Stay updated on Mitsubishi Ufj Trust & Banking Corp with notifications on news.